MetaCap

Kyntra Bio Inc. (KYNB)

NASDAQ: KYNBHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.56-0.24 (-13.33%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

KYNB stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$4.35
52-week range
1.56 – 10.47
Day range
1.56 – 1.81
Volume / Avg
37.38K / 29.96K
Beta
—

52-week range

$1.56$10.47

KYNB stock today

On Nov 20, KYNB ended the session at $1.56, shedding $0.24 (13.33%), versus the S&P 500's 3.70% decline. At this level, KYNB sits near the bottom of its 52-week range of $1.56 to $10.47: 85.1% below the high, set on Dec 16, 2025 and 0.3% above the low. KYNB is down 82.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 81.5%.

Kyntra Bio has posted a net loss over the last twelve months (EPS of -$4.35), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Kyntra Bio

Company profile

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Thane Wettig
Headquarters
San Francisco, CA
Employees
34
IPO year
2014

Financial highlights

Full financials

In fiscal 2025, Kyntra Bio generated $6.4 million in revenue, down 78.3% from fiscal 2024, its first annual decline since 2024. Net income was $183.5 million, for a net margin of 2848.6% versus a median of -160.6% in the prior 5 years. Gross margin was 91.4% (up from 47.5%) and operating margin -712.7%.

Kyntra Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$6.44M$29.62M$46.80M$140.73M$235.31M
Growth-78.26%-36.71%-66.74%-40.19%+33.46%
Net income$183.45M$-47.58M$-284.23M$-293.65M$-290.02M
EPS (diluted)$45.37$-11.89$-2.92$-3.14$-3.14

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$39.67+2442.95%

  • Strong buy 0
  • Buy 3
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $35.00High $43.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-1.61 vs $-3.66
Surprise
+56.01%

KYNB news

All KYNB news

Kyntra Bio peers

Health Care sector
KYNB peer companies
CompanyPrice% ChgMarket capCompare
GTBPGT Biopharma Inc.2.96-6.92%$6.33Mvs KYNB
ACXPAcurx Pharmaceuticals Inc.1.04+0.97%$6.30Mvs KYNB
FBLGFibroBiologics Inc.0.705-15.06%$6.34Mvs KYNB
ADXNAddex Therapeutics Ltd ADR3.47+2.06%$6.08Mvs KYNB
ENVBEnveric Biosciences Inc.1.35-4.26%$6.04Mvs KYNB
BFRGBullfrog AI Holdings Inc.0.3556-8.84%$6.65Mvs KYNB
XCURExicure Inc.0.9001-12.82%$5.89Mvs KYNB
MTVAMetaVia Inc.1.01-7.34%$6.81Mvs KYNB

Indexes, lists and sector

Kyntra Bio stock FAQ

What is Kyntra Bio's stock price today?

KYNB last traded at $1.56 as of Nov 20, 4:00 PM EST, down 13.33% on the day. Prices are delayed at least 15 minutes.

Does Kyntra Bio pay a dividend?

No. Kyntra Bio does not currently pay a regular cash dividend.

Who is Kyntra Bio's CEO?

Mr. Thane Wettig is the chief executive officer of Kyntra Bio Inc., which has about 34 employees.

Has KYNB ever split its stock?

Yes. The most recent KYNB stock split was a 1-for-25 split on Jun 17, 2025.

What is the KYNB 52-week high?

The 52-week high for KYNB is $10.47 and the 52-week low is $1.56. The stock is currently 85.1% below its high.

Compare KYNB